Antibodies are the primary correlate of protection for most licensed vaccines; however, their mechanisms of protection may vary, ranging from physical blockade to clearance via the recruitment of innate immunity. Here, we uncover striking functional diversity in vaccine-induced antibodies that is driven by immunization site and is associated with reduced risk of SIV infection in nonhuman primates. While equivalent levels of protection were observed following intramuscular (IM) and aerosol (AE) immunization with an otherwise identical DNA prime-Ad5 boost regimen, reduced risk of infection was associated with IgGdriven antibody-dependent monocyte-mediated phagocytosis in the IM vaccinees, but with vaccine-elicited IgA-driven neutrophil-mediated phagocytosis in AE-immunized animals. Thus, although route-independent correlates indicate a critical role for phagocytic Fc-effector activity in protection from SIV, the site of immunization may drive this Fc activity via distinct innate effector cells and antibody isotypes. Moreover, the same correlates predicted protection from SHIV infection in a second nonhuman primate vaccine trial using a disparate IM canarypox prime-protein boost strategy, analogous to that used in the first moderately protective human HIV vaccine trial. These data identify orthogonal functional humoral mechanisms, initiated by distinct vaccination routes and immunization strategies, pointing to multiple, potentially complementary correlates of immunity that may support the rational design of a protective vaccine against HIV.
A mong the HIV-1 vaccine concepts evaluated in human efficacy trials, modest protection was observed following IM canarypox prime-protein boost (canarypox-protein) vaccination 1 (RV144 trial) in the absence of broadly neutralizing antibodies or cytotoxic T cell responses but in association with other aspects of the humoral response 2 . Likewise, emerging data from multiple nonhuman primate (NHP) studies point to a critical role for non-neutralizing antibody activities, including antibodydependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), in protection from infection upon viral challenge [3] [4] [5] [6] [7] . Moreover, passive antibody-transfer experiments in humanized mice and NHPs have also illustrated the critical role of antibody functions beyond neutralization, in which the elimination of Fc activity from broadly neutralizing HIV-specific antibodies results in compromised protection 8, 9 . Furthermore, in humans, antibodies to the envelope glycoprotein (Env) V1/V2 variable loops and antibodies that were able to induce ADCC (in the absence of IgA responses) were enriched among RV144 vaccinees that resisted HIV infection 2 . However, questions remain regarding the specific humoral functions that track with protection against SIV, SHIV or HIV and whether they are consistent across studies.
In a previously published NHP vaccine trial, DNA priming followed by recombinant adenovirus type 5 (rAd5) vaccination resulted in substantial antibody-mediated protection from SIV infection 10 . Although protection was linked to the selective neutralization of sensitive clones within the challenge viral swarm, we sought to define whether specific antibody functional mechanisms, beyond the observed low titers of neutralizing antibodies, were enriched among macaques that resisted infection. Moreover, we aimed to further determine the consistency or divergence of humoral correlates of protection induced with the same vaccine regimen administered mucosally. Using a comprehensive and objective antibody Fc-profiling approach, we defined the functional antibody correlates of protection. Phagocytosis was a consistent and key correlate of protection across vaccine arms but was associated with distinct innate immune effector cells and antibody isotypes whose expression was driven by the route of immunization. These data define potential mechanisms of protection against viral infection and provide important insights for HIV vaccine design.
Results
Equivalent protection from infection observed using distinct routes of vaccination. As previously described 10 , 80 Indian-origin These four arms included an empty vector control, SIV Gag, SIV mac239 Env (IM mac239 Env), and a combination of two mosaic SIV Env constructs designed to optimize T cell epitope coverage (IM mosaic Env). Twenty additional animals were subsequently enrolled and received the SIV mac239 DNA/rAd5 regimen mucosally via aerosol (AE) administration (AE mac239 Env). As previously reported, IM vaccination with IM mac239 Env provided significant protection from infection (69% vaccine efficacy), whereas vaccination with IM mosaic Env did not 10 . Notably, for the new study arm designed to address efficacy in the context of a different route of administration, we report that mucosal AE vaccination with AE mac239 Env conferred significant protection from infection ( Fig. 1a: 70% vaccine efficacy). Thus, both IM and AE routes induced immune responses that provided equivalent levels of protection from infection. As previously reported, no association was observed between T cell immunity and risk of infection 10 . Whereas peak, but not set point, viral loads were reduced with both IM regimens, no reduction in virus was observed following AE mac239 Env immunization (Supplementary Table 1 ).
Distinct humoral immune profiles induced by different routes of vaccination.
Given the strong associations previously reported between multiple antibody assessments and the probability of infection in the IM mosaic Env and IM mac239 Env arms 10 , SIVspecific serum antibody responses were systematically profiled to define humoral correlates of reduced risk of infection. The ability of serum antibodies to induce effector functions was quantified by a suite of functional assays, including measures of ADCC and NK cell activation, phagocytic activity mediated by neutrophils (ADNP) and monocytes (ADCP), and complement-dependent cytotoxicity 3 . Lastly, glycosylation and Fc receptor binding profiles of antigen-specific antibodies were defined [11] [12] [13] to link these functional activities to the biophysical and biochemical profiles of the vaccine-specific humoral responses. Responses to a number of variants of SIV Env proteins (gp140, gp120) as well as those directed at specific epitopes, including scaffolded and synthetic variable (V) loop peptides and the constant (C) region peptides C1, C2, and C3, were assessed (Supplementary Table 2 ). No SIV Env-specific humoral immune responses were observed in animals vaccinated with empty vectors or Gag-containing vectors ( Supplementary  Fig. 1a ), and these animals were not considered in analyses profiling the humoral immune response. In contrast, Env-specific humoral immune responses were observed among each of the three Envimmunized vaccine groups (IM mosaic Env, IM mac239 Env, AE mac239 Env), although Env-specific IgG titers were lower in the IM mosaic Env group ( Supplementary Fig. 1a ), as previously reported 10 . Beyond this difference in magnitude, the overall architecture of the humoral immune response induced by the Env-containing vaccine regimens was remarkably different among the three groups of recipients, as evident both in variability across individual humoral response features (Fig. 1b) and in the correlative relationships observed between antibody features (Fig. 1c) , including those determined through functional and biophysical (Fc Array) assessments. In multivariate space, all three regimens could be robustly distinguished ( Fig. 1d and Supplementary Fig. 1b-i) , confirming that the route of immunization shapes the Fc profile of the vaccine-induced immune response.
Vaccine-induced humoral immune responses predict protection across arms. To further define the unique biophysical humoral correlates associated with reduced risk of infection, a Cox proportional hazards model was trained and tested 7 using aggressive feature filtering, along with repeated cross-validation and permutation testing. The final model accurately captured overall survival trends, including differential protection among the arms, in the absence of any knowledge of arm identities (Fig. 2a) . In repeated cross-validation, predictions of risk of infection for individual animals were highly concordant with observed times to infection (representative concordance statistic (C-index): 0.73, P < 10
; Supplementary Fig. 2a) ; this test also distinguished the significantly higher protection observed in the IM mac239 Env and AE mac239 Env study arms as compared to the IM mosaic vaccine recipients (Fig. 2b) . The robustness of this result was established by the significant and substantial difference in predictive accuracy between models trained with actual challenge data compared to permuted data ( Supplementary  Fig. 2b) . Specifically, the final model employed four features as a representative minimal set of features that were most predictive of protection ( Fig. 2c and Supplementary Fig. 2c,d ). Of the three Control IM mosaic Env IM mac239 Env AE mac239 Env Fig. 1 | There is equivalent protection from SIV acquisition in SIV mac239 -immunized animals despite striking Fc-profile differences induced via distinct routes of immunization. a, Kaplan-Meier curves depicting the fraction of animals uninfected in Env-vaccinated and control arms following successive challenges (n = 80 animals). One animal in the IM mosaic Env arm, five animals in the IM mac239 Env arm, and five animals in the AE mac239 Env arm remained uninfected after 12 challenges. Dashed lines depict data previously reported in Roederer et al. 10 ; the solid line depicts newly reported data. b, Heatmaps of humoral responses assessed for Env-vaccinated animals. Rows correspond to animals and columns correspond to the normalized (centered and scaled) Fc array and functional assay readouts (features); high responses are indicated in red and low responses in blue. c, Feature versus feature correlation matrices in heatmap form illustrate correlative relationships between all feature pairs within each Env-vaccinated study arm; correlated responses are indicated in red and anti-correlated responses in blue. d, Partial least-squares (PLS) latent variable (LV) scores biplot using features selected from an arm classification model illustrating that the groups can be separated accurately based on differences in humoral responses. Ellipses correspond to 95% confidence intervals for each group.
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NATurE MEDIcINE positive correlates of protection, two corresponded to the ability of V1a (variable loop) and C1.TR (a constant region 1 sequence variant that was sensitive to neutralization 10 ) peptide-specific antibodies to bind to rhesus Fcγ R2A.4, and one corresponded to the ability of SIV mac239 gp140-specific antibodies to bind to the complement cascade initiating C1q protein. Conversely, C1q-binding SIV smE543 gp140-specific antibodies were predictive of increased risk of infection, revealing both the importance of fine specificity in the humoral response (peptide versus whole protein) as well as particular Fc-binding characteristics (Fcγ R2 versus complement) for predicting protection. Thus models built on Fc-correlates could predict protection from infection, raising the possibility that Fc-effector function could play a critical part in protection from infection following DNA/rAd5 vaccination.
Arm-specific correlates point to distinct mechanisms of humoral immune protection against SIV. Given the differences in humoral responses between arms (Fig. 1) , we further probed the specific humoral profiles, including Fc functions, associated with protection within the two SIV mac239 -immunized vaccine arms using an 
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approach combining feature selection and classification. Distinct Fc profiles were observed among 'susceptible' animals (infected with four or fewer challenges) and more 'resistant' animals (uninfected or infected after ten or more challenges) in both the IM and AE vaccine arms, with animals with 'intermediate resistance' falling between these groups (Fig. 3a,d and Supplementary Fig. 3a-d ). This prediction of protection in the IM arm was achieved with a minimal set of select Fc features (Fig. 3b) , one of which was shared with the Cox proportional hazards model (Fig. 2c) . These features included four variables that were higher in the resistant animals and one variable that was higher in the susceptible animals. The protective features included one antibody effector function-the ability of gp120-specific antibodies to drive ADCP via monocytes-as well as three peptide-specific Fc receptor-binding features, including both V1a-specific antibodies able to engage the rhesus macaque Fc gamma receptor variants Fcγ R2A.4 (shared with the CoxPH model) and Fcγ R3A.3 and G73 (C2 region peptide)-specific antibodies that bind to rhesus Fcγ R3A.3. Conversely, the ability of SIV smE543 -specific antibodies to bind to human Fcγ R3b was a negative predictor of protection, highlighting the existence of peptide-specific responses and the balance between recognition of Env variants associated with protection (SIV mac239 ) and susceptibility (SIV smE543 ). Although the SIV mac239 and SIV smE543 sequences have an overall identity of 83%, sequence variability at sites of immune pressure, such as within the V1V2 loop 10 , may provide a rationale as to why recognition of SIV mac239 is associated with protection and recognition of SIV smE543 is associated with susceptibility, suggesting potentially new sites of functional antibody vulnerability on the viral envelope. Because phagocytes typically express Fcγ R2 receptors but may also express Fcγ R3 upon maturation, the array of biomarkers selected by the model suggests that 'protective' humoral responses mediate their protective functions following rDNA/Ad5 immunization by leveraging both Fcγ R2 and Fcγ R3 receptors to drive viral clearance. Moreover, although the five-feature multivariate profile provided highly significant prediction of protection (r = 0.86, P = 1.6 × 10 −6 ), the level of ADCP alone was also highly correlated with the number of challenges required to infect animals (r = 0.79, P = 3.5 × 10 −5 ), highlighting the mechanistic value of this functional assay in resolving protective IM-induced humoral immune profiles against SIV (Fig. 3c) .
Despite use of an identical immunogen, distinct biomarkers were enriched among protected animals in the AE arm (Fig. 3e) , including the ability of SIV mac239 gp140-specific antibodies to interact with human Fcγ R2a, multiple IgA specificities, the ability of antibodies to drive ADNP, the level of glycan bisection among antigen-specific antibodies, and C1.TR (neutralization-sensitive C1 region peptide variant)-specific antibodies that bind to the rhesus Fcγ R2A.4 variant. Human neutrophils express both Fcγ R3b and Fcα R, enabling them to respond to immune complexes consisting of both or either vaccine-specific IgG and IgA antibodies 14 . Moreover, the addition of the bisecting N-acetylglucosamine (GlcNAc) has been linked to improved Fcγ R3a binding and ADCC 15 , potentially also potentiating ADNP via Fcγ R3b, given its nearly identical extracellular domain to Fcγ R3a 16 . Importantly, both SIV mac239 gp140-specific Fcγ R2a-binding antibodies and G49 (V1b peptide)-specific IgA were strongly associated with protection (Fig. 3f) , arguing for a potential mechanistic collaboration between AE vaccine-specific IgG and IgA in driving ADNP and protection against SIV.
Thus collectively, phagocytic activity was associated with protection in both the IM mac239 Env and AE mac239 Env vaccine arms, albeit through distinct innate immune effector cells and via distinct antibody isotype profiles.
Vaccine route directs unique functional profiles that predict protection from infection. The striking finding that protection was associated with the recruitment of distinct antibody effector functions suggested that distinct antibody effector mechanisms may contribute to reducing the risk of SIV acquisition. Univariate examination of ADCP and ADNP (Fig. 3g,h and Supplementary  Fig. 3e ) activity among the three Env-immunized arms highlighted the clear enhancement of ADCP induced by the SIV mac239 IM immunization compared to both the AE and IM mosaic immunization, as well as the significantly higher levels of ADNP activity induced via AE immunization as compared to the other two vaccine arms. This functional diversity highlights the importance of vaccine route in driving antibody effector profiles. Moreover, Cox modeling analysis, using just these two functional features, yielded a final model (Fig. 3k ) that closely and robustly matched the survival outcomes (Fig. 3i,j and Supplementary Fig. 3f,g ) and differentiated arms. Importantly, ADCP was not elevated among protected animals in the AE arm, nor was ADNP elevated in protected animals in the IM arm, highlighting the distinct phagocytic functional correlates of protection against SIV driven by the route of immunization ( Supplementary Fig. 3h -j).
Vaccine route directs specific isotype selection differences governing antibody functional activity. IgA has both been implicated as a predictor of risk of HIV infection 2 and linked to protection from infection in NHPs 17 . Thus to further probe the nature of the IgG and IgA biomarkers associated with protection in the AE arm, we selectively depleted IgG and IgA antibodies, levels of which varied significantly across arms (Fig. 4a,b ), in plasma samples from IM mac239 Env-and AE mac239 Env-immunized animals, and both ADCP and ADNP were tested. As expected given its high serum abundance, IgG depletion resulted in a significant reduction in ADCP and ADNP activity across both arms (Fig. 4c,d ), revealing the critical role of IgG as the dominant isotype in driving immune complex formation and the effector function of antibodies. Conversely, despite its lower serum concentration, IgA depletion resulted in a significant reduction in ADNP activity in the AE mac239 Env vaccine arm (Fig. 4d) . In contrast, IgA depletion did not significantly impact ADNP in the IM mac239 Env arm (Fig. 4d) , consistent with the lower levels of IgA induced by IM immunization. Collectively, the near-complete loss of ADNP function following either IgG or IgA depletion suggests that in serum, despite the differences in induction of antibody expression associated with route of immunization, these isotypes can work collaboratively to drive the antibody effector function(s) linked with reduced risk of SIV acquisition.
Humoral network analyses distinguish arm-specific protective antibody profiles. We next aimed to define the features linked to the modeled biomarkers of protection, as they may provide further mechanistic clues related to antibody-mediated restriction of SIV. Antibody features that were significantly correlated (|r| > 0.7; Benjamini-Hochberg false discovery rate (FDR) < 0.01) with the biomarkers identified here were defined for the IM mac239 Env (Fig. 4e ) and AE mac239 Env (Fig. 4f ) vaccine arms. Specifically, humoral immune network analyses of the group that received the mac239 Env vaccine highlighted the critical nature of antibodies that interact with Fcγ R2 and Fcγ R3 and of those targeting the SIV macE660 and SIV mac239 antigen, V1a and G73 (C2) peptides as correlates of the biomarkers associated with protection. Conversely, humoral responses targeting SIV smE543 were associated with the correlate of risk. Similarly, network analyses of the AE mac239 Env-vaccinated group pointed to recognition of SIV mac239 , SIV macE660 and SIV macV1V2 specificities via IgA or Fcγ R binding IgG responses. Additionally, analyses were performed to define the specific glycoforms associated with each protective function (ADCP activity in the IM mac239 Env arm and ADNP in the AE mac239 Env). Shared SIV gp120-specific IgG G1 and G2 glycoforms were associated with each mode of phagocytosis ( Fig. 4g and Supplementary Articles NATurE MEDIcINE The robust functional humoral correlates of immunity against SIV identified in this study target known sites of vulnerability 2,10 but diverge functionally by route of immunization, providing a strong rationale for identifying functional correlates and cocorrelates of humoral immunity beyond in vitro neutralization potency. Overall, these data show that distinct innate immune effector mechanisms, which lead to phagocytic clearance, may contribute to restriction of SIV. 
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Cross-study conservation of vaccine correlates. The ultimate identification of a set of minimal correlates of protection, able to predict protection within and across studies, could provide critical insights for the evaluation and development of next-generation vaccines. To define minimal correlates, features associated with protection across study arms and modeling approaches were considered. Four key humoral response characteristics were consistently associated with reduced risk of infection, capturing biologically sound, nonoverlapping, unique variables. These four features included ADNP and ADCP as functional markers and IgA and Fcγ R2A binding activities of vaccine-specific antibodies as biophysical features associated with these functions. These four aspects of the humoral response were both distinct among study arms and predictive of challenge outcomes, capturing both mucosal and parenteral correlates of immunity. To validate the predictive significance of correlates defined by the DNA/rAd5 regimen in an independent vaccine and challenge setting, we assessed the four features in a cohort of animals that were primed with ALVAC and boosted with HIV-recombinant gp120 proteins (ALVAC/protein immunization), analogous to the RV144 HIV vaccine trial in humans 7 .In this study animals were immunized against HIV and challenged with a tier 2 SHIV because this was important for rigorously evaluating the potential breadth of these correlates beyond SIV. Remarkably, two of the four correlates, including Fcγ R2a binding and ADCP, showed significant (P < 0.05) univariate associations with reduced risk of infection (Fig. 5a) . Notably, protection outcomes were accurately predicted in the ALVAC/protein-immunized animals using a model based on the four features identified as correlates of protection in the DNA/rAd5-immunized animals (ADCP, ADNP, Fcγ R2A, and IgA), and trained using data only from the DNA/rAd5-immunized (Fig. 5b) . This combination of the four DNA/rAd5-defined biomarkers defined in the SIV study exhibited better agreement with the challenge outcome (r model = 0.74) than any individual biomarker (r best individual feature = 0.67) for the ALVAC/protein HIV vaccine, further supporting the robustness of the co-correlate signature across vaccine strategies. Finally, the co-correlates accurately captured overall survival trends (Fig. 5c ). These data argue for conserved correlates of immunity against both SIV and SHIV that are present across different immunization regimens and different routes of administration. Protection appears to be governed by the ability of virus-specific antibodies to drive rapid phagocytic clearance, likely through the recruitment of distinct innate immune effector cells.
Discussion
Here we aimed to define whether functional humoral correlates could explain the previously observed differences in vaccine efficacy following IM immunization with different Env antigens while simultaneously determining whether these correlates are conserved or diverge in the setting of mucosal vaccination with the same vaccine product. Reduced risk of infection following both IM and AE vaccination were strongly associated with the induction of unique Fc effector profiles among the vaccinated animals, driven by route of immunization. Remarkably, despite the striking differences in IM and AE vaccine-induced Fc profiles, protection was associated with phagocytosis in both vaccine arms. However, within-arm protection was associated with unique Fc-biomarker profiles and was marked by elevated IgG and ADCP in the IM mac239 Env-immunized animals versus elevated IgA and ADNP in the AE mac239 Env-immunized animals. Importantly, each correlate did not predict protection in the converse arm, and total IgG responses had no relationship to challenge outcomes overall. Moreover, a combined correlate signature defined from both the AE mac239 Env and IM mac239 Env arm could accurately predict protection in a separate vaccine study using distinct immunogens (ALVAC/protein) and a SHIV challenge. These data point to multiple specific functional correlates (that is, number of challenges required to achieve infection) in the ALVAC/protein-immunized animals (n = 18 animals; two-sided P values for Spearman's rho). b, Biplot depicting the correlation between observed and predicted challenge outcomes of ALVAC/protein-immunized animals based on the challenge outcome regression model learned from the DNA/rAd5 vaccine (n = 18 animals; two-sided P-values for Spearman's rho). c, Survival curves depict actual and predicted infections using a Cox proportional hazards model using the integrated four cocorrelates (n = 18 animals; P value calculated by two-sided log-rank test).
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of protective humoral immunity against SIV or SHIV; antibodymediated phagocytosis associated with the deployment of different innate effector cells and induced in a vaccine route-specific manner was significantly associated with a reduced risk of infection. Although there are a number of known and likely additional yet-to-be-characterized differences in human and macaque antibodies 18, 19 , Fcγ Rs 20, 21 , and expression profiles 22 of Fc-receptors on effector cells, the systems show evidence of converging evolution, and studies in both species have suggested relationships between antibody effector functions and protection. For example, previous correlates analyses following Ad26 vaccination in NHP pointed to a role for ADCP in protection 3, 4 . Here, ADCP was associated with reduced risk of infection in both DNA/rAd5 IM-and ALVAC/ protein-immunized animals, suggesting that ADCP may represent a common correlate of protection following IM vaccination. Furthermore, vaccine-specific IgG3 antibody levels, which were associated with a reduced risk of infection in the moderately protective RV144 vaccine 23 , also correlated with robust ADCP 24 , further suggesting that ADCP may also track with enhanced protection in humans. Given the abundance of phagocytic cells within mucosal tissues 25 , as well as their recruitment among the first infiltrators upon tissue assault 26, 27 , ADCP represents a promising mechanism for antibody-mediated control and clearance of both cell-free and cell-associated virus.
Surprisingly, although ADCP was linked to protection following IM vaccination, protection following mucosal vaccination was associated with a remarkably different set of biomarkers, including elevated levels of IgA and ADNP. Decades of research have highlighted the opportunities to skew immunity via immunization within different immune compartments, including muscle, skin, and within different mucosal compartments (mouth, nose, vagina, etc.) 28 . For example, nasal immunization has been associated with the induction of both IgA and IgG responses in human cervicovaginal secretions [29] [30] [31] , potentially providing a unique opportunity to harness particular innate immune effector cell functions localized at sites of vulnerability to infection. Moreover, given the abundance of neutrophils, both in the blood and within the female reproductive tract, as well as their ability to be rapidly migrate to sites of injury and infection, the combination of IgA and IgG may uniquely leverage neutrophil activity and deploy a broad array of antipathogen activities, including phagocytosis, degranulation, and the formation of DNA neutrophil extracellular traps (NETs) involved in trapping and preventing infectious spread 32 . However, given both the immunoprotective and immunopathological roles of neutrophils, balanced IgG:IgA responses may be key to leveraging the speed and antipathogen activity of these innate effectors.
Immune correlates of risk in the RV144 trial suggested that among vaccine recipients, IgA levels were associated with enhanced risk of infection 2 , evidencing the possibility that they may compete for antigen and block IgG activity 33 . However, network analyses in case-control samples from the RV144 vaccine trial 34 suggested that subjects that generated elevated IgA levels had lower IgG levels and specifically generated lower IgG3 antibody responses, which were associated with reduced risk of infection 23 and polyfunctional activity 24 . Moreover, previous passive transfer studies in NHP have demonstrated the protective activity of IgA antibodies 35 . Moreover, consistent with the possibility that elevated IgA might be a surrogate rather than mechanistically involved in reducing protection, IgA levels were not associated with risk of infection in ALVAC/protein-immunized monkeys 7 . Here we observed that IgA can work collaboratively with IgG to drive both ADNP and ADCP. Moreover, IgA-mediated immunity in the AE vaccine arm was linked to viral targets within the V1V2 loop, highlighting the importance of targeting key sites of vulnerability via functional antibody isotypes. Thus, the induction of IgA antibodies that synergize with IgG may provide an opportunity to direct additional innate immune effector function(s) and enhance protection from infection.
Overall, this comprehensive analysis of immune correlates strongly argues for a role for functional antibodies in reducing the risk of SIV and SHIV acquisition. Moreover, while several antibody effector functions, including ADCC and complement activation, were also interrogated in this study, only phagocytic functions mediated by monocytes or neutrophils and associated with IgA or IgG were associated with reduced risk of infection across vaccine regimens and challenge viruses. These results demonstrate that protection against SIV challenge may be achievable via the induction of antibodies that promote phagocytosis via distinct innate Fc-effector cell types and whose isotypes are naturally controllable via the route of immunization. Further, such effector activities are potentially required for distal eradication of the virus upon escape of viral, infected cells beyond the mucosal compartment 36 . Importantly, we demonstrate that multiple mechanisms may protect against viral infection, suggesting that vaccines eliciting a combination of antibody types and that a combination of phagocytic activities may be more potent. Thus, efforts to direct the humoral immune response to sites of vulnerability while simultaneously leveraging the potent antiviral activity of antibody Fc-effector functions may contribute to the rational design of a protective vaccine against HIV.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0161-0.
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Methods Study cohort. DNA/rAd5 study. 80 Indian origin rhesus macaques were immunized IM with a DNA prime-rAd5 boost with four varying immunogens 10 . Twenty additional animals were subsequently enrolled and received one of the same vaccine regimens delivered mucosally via AE administration. The control group received empty vectors, whereas the IM and AE arms received SIV mac239 Env sequence inserts (83% sequence identify with challenge strain), and the mosaic Env group received two SIV Env mosaic immunogens 37 (78 and 87% sequence identity to the challenge virus) designed to optimize coverage of T cell epitopes present among diverse virus strains via the IM route. The fifth group received only SIV Gag immunization. All animals received three injections of DNA at 4-week intervals, followed by rAd5 vaccination at week 30, and were randomized across groups for TRIM5α alleles, gender, age, and weight. Animals were challenged each week beginning at week 53 with an intrarectal administration of smE660 at a dose that infected 30% of control animals per exposure 38 for either a period of 12 weeks or until they exhibited detectable infection as defined by plasma viremia. Virology assessments were performed as previously described via real-time PCR and singlegenome amplification 10 . No differences were observed in FcR genotype across groups or with protection. Antibody assessments were performed at the peak (2 weeks) post-boost time point.
ALVAC/protein study. 26 Indian origin male and female rhesus monkeys were vaccinated IM with ALVAC (vCP1521; Sanofi Pasteur) and recombinant Env gp120 protein(s) in GLA-SEM (IDRI-EM107) 7 Animals were then challenged intrarectally with SHIV-1157(QNE)Y173H weekly for a period of 8 weeks or until they exhibited detectable viremia 7 . Antibody assays for this study were reported previously 7 . All animals were handled in accordance with the standards of the American Association for the Accreditation of Laboratory Animal Care (AAALAC), and work met National Institutes of Health (NIH) standards as set forth in the Guidelines for Care and Use of Laboratory Animals.
Effector function assays. The functional activity of SIV-specific antibodies was determined in a number of cell-based assays 3, 39, 40 (Supplementary Table 2 ). Functional assays were performed in triplicate, with the exception of the NK activation assay, which was performed in duplicate. Replicates of assays performed using primary cells or primary plasma as a source of effectors or complement were performed across multiple donors. Averages across replicates are reported.
Antibody-dependent cellular phagocytosis. ADCP was determined using antigencoated fluorescent beads, as described 41, 42 . Briefly, fluorescent, streptavidinconjugated microspheres were coated with chemically biotinylated SIV mac239 gp120 (Immune Technology) for 2 h at 37 °C and washed with 0.1% BSA in PBS. The antigen-coupled beads were incubated with diluted plasma for 2 h at 37 °C, washed with PBS to remove unbound antibodies, and then incubated with 2.5 × 10 4 THP-1 cells overnight at 37 °C. Cells were then fixed with 4% paraformaldehyde solution and analyzed on a flow cytometer. A phagocytic score was derived as an integrated mean fluorescence intensity (MFI) by multiplication of the fraction of the percent and MFI of bead-positive THP-1 cells.
Antibody-dependent cellular cytotoxicity. ADCC was tested using a rapid fluorescent ADCC assay, which assesses the ability of antibodies to drive primary NK cells to lyse gp120-pulsed target cells 43 . Briefly, CEM.NKr target cells were pulsed with SIV mac239 gp120 protein (Immune Technology) at 60 μ g/mL and then labeled with the membrane dye PKH26 and the intracellular dye CFSE. NK cells were enriched from healthy donor whole blood by negative selection using RosetteSep (Stem Cell Technologies). Purified IgG (100 μ g/mL) was mixed with the labeled CEM.NKr cells, and then NK cells were added at an effector:target ratio of 10:1 and incubated for 4 h at 37 °C. Cells were then fixed and analyzed by flow cytometry. gp120-specific lysis was measured as the percentage of PKH26 + CFSE-CEM.NKr target cells after incubation.
Antibody-dependent neutrophil phagocytosis. ADNP was determined using an adaptation of a flow cytometry-based phagocytic assay described previously 41, 42 . Briefly, fluorescent, streptavidin-conjugated microspheres were coated with chemically biotinylated SIV mac239 gp120 (Immune Technology) for 2 h at 37 °C and washed with 0.1% BSA in PBS. The antigen-coupled beads were incubated with a 1:100 dilution of plasma for 2 h at 37 °C and washed with PBS to remove unbound antibodies. White blood cells (WBCs) were isolated from healthy donor blood anticoagulated with acid citrate dextrose by ACK lysis of red blood cells. 5 × 10 4 WBCs were added to the opsonized beads and incubated for 1 h at 37 °C and then stained with anti-CD66b-Pacific Blue (Biolegend). Cells were then fixed with 4% paraformaldehyde solution and analyzed on a flow cytometer. A phagocytic score was derived as an integrated MFI by multiplication of the fraction of neutrophils that phagocytosed one or more opsonized beads by the MFI of this population.
Natural killer cell activation. An assay to determine natural killer (NK) cell activation (NKA) state based on the expression of surface CD107a and intracellular production of interferon (IFN)-γ and macrophage inflammatory protein (MIP)-1β was performed as previously described 3 . NK cells were isolated from whole blood from healthy donors using negative selection with RosetteSep (STEMCELL Technologies; cat. no. 15065), added to a SIV mac239 gp120-absorbed plate with purified IgG, anti-CD107a-phycoerythrin (PE)-Cy5 (BD; cat. no. 555802), brefeldin A (Sigma; cat. no. B7651), and GolgiStop (BD; cat. no. 554724), and incubated for 5 h at 37 °C. After the incubation, cells were stained for surface markers using anti-CD16-allophycocyanin (APC)-Cy7 (BD; cat. no. 557758), anti-CD56-PE-Cy7 (BD; cat. no. 557747), and anti-CD3-Alexa Fluor 700 (BD; cat. no. 557943) and then were stained intracellularly with anti-IFN-γ -APC (BD; cat. no. 340449) and anti-MIP-1β -PE (BD; cat. no. 550078) after treatment with Perm A and B solutions (Invitrogen; cat. no. GAS004). Cells were then fixed in 4% paraformaldehyde and analyzed by flow cytometry. NK cells were defined as CD3-negative and CD16-positive and/or CD56-positive, and the percent of NK cells positive for each marker was determined.
Antibody dependent complement deposition. The ability of donor antibodies to induce complement component C3b deposition on SIV mac239 gp120-coated target cells was assessed by flow cytometry as previously described 3 . Briefly, CEM-NKr target cells were pulsed with gp120SF162 (60 μ g/ml) and then incubated with purified antibody at a concentration of 100 μ g/mL and freshly harvested HIVnegative donor plasma diluted 1:10 with veronal buffer 0.1% gelatin as a source of complement for 20 min at 37 °C. Following a wash with 15 mM EDTA in PBS, cells were fixed and complement deposition was detected by staining with antiC3b-FITC (Cedarlane; cat. no. CL7632F). The proportion of C3b-positive cells was determined based on negative controls, in which heat-inactivated donor plasma was used.
Fc array. The quantity and qualitative features of HIV-specific antibodies were evaluated using a custom multiplex array in which SIV-specific antibodies were characterized according to their titer (anti-IgG, anti-IgA) and ability to interact with human and/or rhesus innate immune antibody Fcγ R (Fcγ RIIa, IIIa, IIIb and their major allotypic variants 20, 44 ) and human C1q, an initiator of the complement cascade, essentially as previously described 13 . Previous studies show that these low-affinity human and rhesus Fcγ R molecules generally exhibit consistent binding preferences for rhesus IgG types 20 . FcR (Fcγ R and C1q) was biotinylated either chemically at a molar ratio of 5 mol biotin per mol of protein using EZ-Link Sulfo-NHS-SS-Biotin (Pierce) or site-specifically via BirA-mediated enzymatic modification (Avidity). Immediately before use, each biotinylated detection reagent was mixed with a 1/4th molar ratio of Streptavidin-PE (Prozyme) and diluted to a final concentration of 1.0 µ g/mL in Assay Buffer (PBS + 0.1% BSA + 0.05% Tween). The ability of antigen-specific antibodies to bind to these detection reagents was assessed across a diverse panel of HIV antigens coupled to uniquely fluorescently coded magnetic beads (Luminex Corp.) (Supplementary Table 2 ) as follows.
A working mixture of coupled microspheres was added to dilute plasma in black, clear-bottom 384-well plates (Greiner Bio One). Following incubation for 2 h at RT on an XYZ plate shaker (IKA), plates were washed, and antigenspecific antibody was detected using the tetrameric PE-conjugated detection reagents described above at 1.0 µ g/mL, or r-PE-conjugated anti-Ig secondary reagents at 0.65 µ g/ml, with 50 µ L/well. After a 1-h incubation at RT on a shaker, beads were washed five times with 65 µ L of sheath fluid (Luminex 40-75680), and microspheres were resuspended in 40 µ L of sheath fluid. A Bio-Plex array reader (FlexMap 3D, Luminex Corp) detected the microspheres, and binding of each PE-functionalized detection reagent was measured to calculate a Median Fluorescence Intensity (MFI). These features were named according to the following convention: 'detection reagent.antigen. ' Fc Array measurements were preprocessed for quality, eliminating measurements that had a per-arm median MFI value of less than 500 across the three vaccine arms. After this filtering step, a total of 109 features remained, which were considered in the classification and survival analyses.
Antibody depletions. IgG and IgA were depleted using isotype specific CaptureSelect Affinity Matrix resin (ThermoFisher). Specifically, 100 µ L of 1:10 diluted plasma was added to 50 µ L of resuspended and washed resin (based on 8 mg/mL binding capacity) and incubated for 1 h with end-to-end mixing at RT. The depleted fraction (flow through) was collected by centrifugation for 2 min at 1,500 r.p.m. to eliminate the target isotype. Depletion was confirmed via luminex analysis, and the concentration of sample was assessed by ELISA to establish concentrations of flow through for functional experiments in comparison to undepleted (control) plasma.
Glycan analysis. A capillary electrophoresis-based technique for analyzing plasmaderived polyclonal IgG glycosylation was used to determine the relative abundance of glycan structures decorating gp120-specific and total plasma IgG, as previously described 12 . Briefly, glycans were released from IgG with the N-linked glycosidase PNGase F, were fluorescently labeled via reductive amination with 8-aminopyrene-1,3,6-trisulfonic acid, separated from unreacted dye, and analyzed on an Agilent 3130XL ABI DNA sequencer. Peak identities were determined by exoglycosidase reactions and use of glycan standards, and the prevalence of each glycan species was determined by peak area integration with a custom script. The prevalence Articles NATurE MEDIcINE of 19 individual glycoforms and 6 summary glycosylation state assessments were determined (Supplementary Table 2 ). Summary glycosylation characteristics, such as level of galactosylation (G) and sialylation (S), and presence of absence of fucose (F) or bisecting GlcNAc (B) were compiled by summing individual glycoforms.
Data analysis and visualization.
Basic data analysis and visualization were performed using GraphPad Prism along with in-house scripts developed either for the R statistical computing environment 45 (supported by standard R packages caret, ggplot2, and gplots) or the Matlab statistical computing environment (supported by the Statistics and Optimization toolboxes). Network visualizations were performed using Cytoscape 46 . Raw data are available in Supplementary Information.
Classification of vaccine arms. Classification models were trained to distinguish animals between the three vaccine arms on the basis of measured functional, biophysical and biochemical humoral immune responses. Models were built using an approach similar to one described previously 34 -a combination of the least absolute shrinkage and selection operator (LASSO) 47 for feature selection and then classification using the LASSO-selected features (Supplementary Code File 1) . The robustness of this modeling approach was evaluated using repeated fivefold cross validation. For each fivefold cross validation run, primates were randomly divided into five subsets. This was done such that for each fold, four subsets served as the training set, and the fifth one served as the test set, with each subset serving as the test set once. For each such fold, LASSO-based feature selection was performed using only the four subsets designated as the training set for that fold, with the coefficient for the LASSO penalty term determined via an additional internal fivefold cross validation using only the fold-specific training dataset. A fold-specific support vector machine (SVM) 48 classifier (linear kernel with default Matlab parameters) was trained using the LASSO-selected features and training data for that fold (thus each fold may have a different LASSO penalty parameter, different features and different coefficients). This fold-specific classifier was then used to predict labels for the primates in the test set for that fold. This process was performed for each of the five folds and repeated 100 times for different fivefold splits. Visualizations of latent variables from a partial least-square discriminant analysis (PLSDA) 34, 49 model trained on the LASSO-selected features are reported. The significance of the predictive performance of the models was assessed with two complementary control approaches. As described above, the 100 repetitions of fivefold classification generated a distribution of model classification accuracies. Corresponding model accuracy distributions were generated for two types of control models. The first control model followed a permutation testing 50 approach, by randomly shuffling the data with respect to the arm labels before feature selection, within a cross validation framework. This generates permutationspecific control models. The features themselves were not shuffled, preserving the correlation structure of the data. The second control used, within a cross-validation framework, randomly selected size-matched subsets of features (the size-matching was fold-specific). Here too the correlation structure of the data was preserved. For each control model approach, these processes were repeated 100 times to generate a distribution of model of accuracies observed in the context of permuted data and randomly selected size-matched feature sets.
The entire procedure was repeated across all five cross validation folds. After running through all five folds, we compared the predicted arm label for each primate (since each primate was in the test set in exactly one of the five cross validation folds) to the true arm labels, and we obtained a true classification accuracy (equivalent to average classification accuracy across folds as the folds are of equal size). We computed the P value as the tail probability of the true classification accuracy in the distribution of control model classification accuracies. We reported median P values across 20 independent cross validation replicates.
LASSO-regularized multinomial logistic regression was also performed to identify humoral properties able to classify animals into their respective vaccine arm. These classifier models were trained via the R package 'glmnet' 51 with default options (Supplementary Code File 2) . To enable visual inspection of a single set of model coefficients, a final model was trained using the penalty parameter (lambda) that achieved the lowest cross-validation classification error. To visualize classification confusion and log odds predictions of arm, a single run of tenfold cross-validation was performed; the predicted class log odds were obtained from the ratio of the predicted probability for the true arm to the maximum of the predicted probabilities for the other arms. Predictive performance was assessed in terms of balanced accuracy (mean true positive rate) over 100 repetitions of tenfold cross-validation, with training/testing splits determined randomly while ensuring that each testing set included an equal number of animals from each vaccine arm. Robustness was established through permutation testing 50 , randomly shuffling the arm labels and performing cross-validation following the exact same process as with the original data (that is, training, feature selection, and classification). This process was repeated 100 times, randomly shuffling the arm labels for each repetition. Random-selection models were trained by randomly selecting feature sets size-matched to the number of features in the final model and were evaluated using the same cross-validation framework as with the original data. A random size-matched subset of features was selected for each repetition of cross-validation. Robustness was quantified in terms of effect size (Cliff 's ∆) analysis of the cross-validation versus permutation testing balanced accuracy distributions, as well as the tail probability of the average balanced accuracy from repeated crossvalidation with actual data versus the distribution from permutation testing.
Survival analysis.
An updated version of a previously described multivariate survival analysis approach 7 was used to train Cox proportional hazards (CoxPH) regression models 52 to predict the risk of infection at each challenge point using Fc Array features (Supplementary Code File 2). Key steps are as follows:
Feature preanalysis. To aid the modeling process in dealing with redundancy, features were clustered according to their profiles across all animals (ignoring infection status) using hierarchical agglomerative clustering 53 , as implemented by the R function 'hclust' from the 'stats' package 45 with the 'ward.D2' method. The tree was cut so as to yield between 5 to 15 clusters, and a set of 9 clusters was selected as maximizing the distance between the nearest cluster centroids.
Cross-validation. The animals were split into 10 subsets, or folds, such that each fold contained an equal number of animals from each of the vaccine arms. For each fold, the animals from the remaining folds were used as the training set, and the animals in the fold as the test set.
Feature filtering. Within the cross-validation, the features in each cluster were ranked by their correlations with time-to-infection for the training set animals, as evaluated by polyserial correlation coefficient 54 , which measures correlation between discrete and continuous variables. The top ranked feature from each cluster was shortlisted for consideration in modeling. Pair-wise correlations among the shortlisted features were minimized by selecting features in decreasing order of polyserial coefficient magnitude and eliminating subsequent features that were highly correlated (Pearson correlation coefficient > 0.7) to the selected features.
Model training. CoxPH models were trained using the R package 'survival' 55 , with greedy backward feature elimination 56 employed to select features during training by iteratively eliminating features as long as the training set likelihood was no more than 25% worse than an initial model trained using all of the shortlisted features.
Risk prediction. As the CoxPH model is semiparametric, with the baseline hazard function unspecified, the absolute risk of an individual animal cannot be estimated. Hence, risk of infection for each animal was predicted relative to the mean of all animals, which provides a constant baseline to compare risk across all animals. Predictive performance was assessed using the Concordance index (C-index) metric 57 over 100 repetitions of tenfold cross-validation.
Representative run and final model. A representative run of tenfold cross-validation was performed using the most frequent features, defined as those appearing in at least 50% of the models obtained over the repeated cross-validation. A final model was trained using all the animals and the same set of high-frequency features to predict arm-wise risk (aggregate Kaplan-Meier curves) using the 'mean' animal of each arm. To do so, the probability of infection at each challenge point for the three vaccine arms was estimated by making predictions on mean animals, whose features represent the mean of the features over the respective arms' animals. The 'survfit.coxph' function in R package 'survival' 55 was used to estimate these probabilities. The predicted and observed probabilities for each group were compared using the log-rank statistic. A high log-rank statistic P value favors the null hypothesis that the two curves are similar.
Robustness. Permutation testing was performed by randomly shuffling the challenge labels and then following the exact same cross-validation approach as was used for the actual labels (that is, feature filtering, model training, and risk prediction). The process was repeated 100 times, randomly shuffling the challenge labels for each repetition. Random selection models were trained by randomly selecting feature sets size-matched to the number of features in the final model (see below) and were evaluated using the same cross-validation framework as with the actual data. A random size-matched subset of features was selected for each repetition of cross-validation. Robustness was quantified in terms of effect size (Cliff 's ∆) analysis of the cross-validation versus permutation testing C-index distributions, as well as the tail probability of the average C-index from repeated cross-validation versus the distribution of C-indices from permutation testing.
Co-correlates. Fc features correlated to each feature in the final model (Pearson correlation coefficient > 0.75) were considered as possible substitutes. For each such possible substitute, a tenfold cross-validation was performed to assess performance of a variant of the final model using the substituted instead of the corresponding final feature.
Analysis of functional data. Risk predictions were made with the two functional measurements that showed distinct arm-specific responses (ADCP and ADNP), the feature filtering and greedy backward elimination strategies were not needed, so standard bivariate CoxPH models were directly trained using the 'survival' 55 R package. The predictive performance and robustness of the models were again evaluated using the 100-repeated tenfold cross-validation and permutation testing approaches described above. 
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Sample size
Statistical power was calculated across historical non-human primate vaccine studies by NIH/VRC personnell.
Data exclusions No data was excluded.
Replication
All assays were run in duplicate across 2 separate experiments.The same functional correlate was defined across arms of the study providing biological validation. Additionally, the correlates were validated in a second vaccine study, using a completely different vaccine approach, demonstrating the translatability of the correlate.
Randomization Animals that were A01 and Trim5 polymorphism positive were excluded from the vaccine study. All other animals were randomized across arms in both vaccine studies as previously published in Nature and Nature Communications.
Blinding
Plasma samples from both studies were shipped blinded to the Alter/Ackerman labs. The data was then returned to Drs. Roederer and Haynes who then unblinded the data for analysis.
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